The MPN News feed provides frequent updates on the latest happenings in the MPN World. Fresh content, with brief summary is automatically updated frequently from reliable sources. Just click on the red hyperlink to pull up the complete news item.
Make PV Reporter your “starting point” for all MPN related news.
-
8 updates on COVID-19 drugs in development
by mpn_admin at 2:14 pm
Hundreds of clinical trials in the U.S. and abroad are looking for potential drugs to treat or prevent COVID-19. As of July 6, […]
-
Texas Virtual MPN Workshop (TMW) Aug 27-28, 2020
by mpnadmin at 10:05 am
The UT Health San Antonio Mays Cancer Center and MD Anderson Cancer Center invite you to attend the TEXAS VIRTUAL MPN WORKSHOP (TMW) 2020: […]
-
Ruxolitinib’s Impact on OS in the Real World for Elderly Patients Diagnosed With MF
by mpn_admin at 3:36 pm
In the real-world, ruxolitinib’s approval to treat myelofibrosis has improved overall survival (OS) for elderly patients. Two […]
-
Protagonist Therapeutics Receives Orphan Drug Status for PTG-300 in Treatment of PV
by mpn_admin at 2:45 pm
The U.S. Food and Drug Administration granted orphan-drug status to Protagonist Therapeutics Inc.’s PTG-300 to treat a rare form of […]
-
MPN QOL Survey
by mpnadmin at 2:13 pm
The Mayo Clinic and Myeloproliferative Neoplasm Quality of Life Study Group are conducting an international research survey to investigate […]
-
EHA Poster: Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib
by mpn_admin at 2:32 pm
Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and […]
-
EHA Poster-MANIFEST Study for CPI-0610
by mpn_admin at 2:17 pm
CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) — Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that three […]
-
Ruxolitinib shows promise in severe COVID-19
by mpn_admin at 2:48 pm
Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in […]
-
FDA Approves Next Step for PharmaEssentia’s Ropeginterferon alfa-2b in PV Patients
by mpn_admin at 2:23 pm
June 4, 2020, Burlington, MA – PharmaEssentia Corporation, a global biopharmaceutical innovator leveraging deep expertise and proven […]
-
CTI BioPharma Enrolls First Patient in COVID-19 PRE VENT Trial
by mpn_admin at 1:45 pm
CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of […]
-
BMS Partnering on COVID-19 Emergency Food Assistance
by mpn_admin at 3:40 pm
Team Rubicon Announces the COVID-19 Emergency Food Assistance Program in Collaboration with Patient Advocate Foundation and Funded by the […]
-
MPN Patient Survey on COVID-19
by mpn_admin at 3:27 pm
The University of Aberdeen and Queen’s University Belfast are investigating the impact of COVID-19 on MPN patients and caregivers. […]
-
Dr. Mesa and Antje Hjerpe discuss Treatment for ET
by mpnadmin at 7:08 pm
The post Dr. Mesa and Antje Hjerpe discuss Treatment for ET appeared first on MPN Education Foundation.
-
Date TBD – The 8th Seattle Patient Conference
by mpnadmin at 11:31 pm
This event has been temporarily postponed due to COVID-19. New date will be announced soon – Please check back! WHO SHOULD […]
-
Myeloproliferative Neoplasma (MPNs) Update – Spring 2020
by mpnadmin at 10:27 pm
The post Myeloproliferative Neoplasma (MPNs) Update – Spring 2020 appeared first on MPN Education Foundation.
Follow Us!